Early studies of our research group found that TFPI-2 showed low or negative expression in highly invasive breast cancer cell lines because the CpG islands in TFPI-2 promoter was hypermethylated, and DNA methylation in the promoter region induced inactive chromatin structure and decreased KLF6 binding to its DNA binding sequence [17]. The gene discussed is TFPI2; the disease is breast cancer.